Genscript Bio Gets Booster From Subsidiary’s New Cancer Drug
子公司新产品贡献大 金斯瑞生物迎收成期

The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the market
金斯瑞生物科技旗下传奇生物开发的CAR-T细胞治疗药Carvykti，上市9个月的销售收入已超过1.34亿美元。